

X-linked retinitis pigmentosa – Pipeline Insight, 2021

<https://marketpublishers.com/r/X3B9B11CBA34EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: X3B9B11CBA34EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "X-linked retinitis pigmentosa – Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in X-linked retinitis pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

X-linked retinitis pigmentosa Understanding

X-linked retinitis pigmentosa: Overview

X-linked retinitis pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss. Total population affected by X-linked retinitis pigmentosa is 1 in 4000 people across the world. Also, as it is a recessive disorder, males are more affected as compared to females, who have two X chromosomes making them carrier for the disorder. Early symptoms for X-linked retinitis pigmentosa includes night blindness, and progressive loss of visual field.

"X-linked retinitis pigmentosa- Pipeline Insight, 2021" report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the X-linked retinitis pigmentosa pipeline landscape is provided which includes the disease overview and X-linked retinitis pigmentosa treatment guidelines. The assessment part of the report embraces, in depth X-linked retinitis pigmentosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, X-linked retinitis pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence X-linked retinitis pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve X-linked retinitis pigmentosa.

X-linked retinitis pigmentosa Emerging Drugs Chapters

This segment of the X-linked retinitis pigmentosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

X-linked retinitis pigmentosa Emerging Drugs

BIIB 112 (NSR-RPGR): Biogen

Biogen's lead drug candidate, BIIB 112 (NSR-RPGR), is a class of gene therapy molecule which consists of standard AAV8 vector carrying a codon-optimized RPGR gene. The drug is in Phase II/III stage for the treatment of rare X-linked retinitis pigmentosa and has been designated orphan drug status. The trial is carried out to evaluate the tolerability as well as the stability of the drug in improving central vision.

4D-125: 4 D Molecular Therapeutics

4D Molecular Therapeutics "lead" drug 4D-125 is currently being evaluated for the

safety and maximum tolerance dose for the treatment of X-linked retinitis pigmentosa. 4D-125 is an AAV gene therapy with an optimized vector designed to deliver a functional RPGR gene copy to the photoreceptors in retina.

Further product details are provided in the report.....

X-linked retinitis pigmentosa: Therapeutic Assessment

This segment of the report provides insights about the different X-linked retinitis pigmentosa drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in X-linked retinitis pigmentosa

There are approx. 5+ key companies which are developing the therapies for X-linked retinitis pigmentosa. The companies which have their X-linked retinitis pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

- Late-stage products (Phase II/III)

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

X-linked retinitis pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

X-linked retinitis pigmentosa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses X-linked retinitis pigmentosa therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging X-linked retinitis pigmentosa drugs.

X-linked retinitis pigmentosa Report Insights

X-linked retinitis pigmentosa Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

X-linked retinitis pigmentosa Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing X-linked retinitis pigmentosa drugs?

How many X-linked retinitis pigmentosa drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of X-linked retinitis pigmentosa?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the X-linked retinitis pigmentosa therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for X-linked retinitis pigmentosa and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Biogen

4 D Molecular therapeutics

Applied Genetics Technology Corporation

Key Products

BIIB-112 (NSR-RPGR)

4D-125

AGTC501

Contents

Introduction

Executive Summary

X-linked retinitis pigmentosa: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

X-linked retinitis pigmentosa – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

X-linked retinitis pigmentosa companies' collaborations, Licensing, Acquisition -Deal

Value Trends

X-linked retinitis pigmentosa Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase II/III)

Comparative Analysis

BIIB 112 (NSR-RPGR): Biogen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase I/II)

Comparative Analysis

4D-125: 4 D Molecular Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

X-linked retinitis pigmentosa Key Companies

X-linked retinitis pigmentosa Key Products

X-linked retinitis pigmentosa- Unmet Needs

X-linked retinitis pigmentosa- Market Drivers and Barriers

X-linked retinitis pigmentosa- Future Perspectives and Conclusion

X-linked retinitis pigmentosa Analyst Views

X-linked retinitis pigmentosa Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for X-linked retinitis pigmentosa
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for X-linked retinitis pigmentosa
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: X-linked retinitis pigmentosa – Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/X3B9B11CBA34EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/X3B9B11CBA34EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970